3 results · Page 1 of 1

Swipe the table sideways for more columns.

TrialConditionsStatusPhaseUpdatedMore infoNCT ID
Evenamide, a Glutamate Release Modulator, as Add-On to Standard of Care in Subjects With Documented Treatment-Resistant SchizophreniaSchizophrenia Spectrum and Other Psychotic Disorders, Schizophrenia, Treatment-Resistant, psychiatric disorder, schizophreniaRecruitingPhase 32026-09-10NCT07184619
Open-label, Long-term Safety, Efficacy, and Pharmacokinetics Study of Vibegron in Pediatric Subjects 2 Years to < 18 Years of Age With NDO and on CICCNS demyelinating autoimmune disease, Congenital Abnormalities, Congenital, Hereditary, and Neonatal Diseases and Abnormalities, Hernia, Infections, Neoplasms by Site, Neuroinflammatory Diseases, Paraneoplastic Syndromes, Nervous System, Pathological Conditions, Anatomical, Pathological Conditions, Signs and Symptoms, acute transverse myelitis, autoimmune disease, autoimmune disorder of the nervous system, central nervous system disorder, central nervous system infectious disorder, central nervous system malformation, demyelinating disease, immune system disorder, injury, meningocele, myelitis, neoplasm, nervous system disorder, nervous system injury, neurodegenerative disease, paraneoplastic syndrome, spinal cord disorder, spinal cord injuryRecruitingPhase 2 / Phase 32026-06-15NCT05491525
Autologous Dentine Graft Compared to Xenograft in Managing Periodontally Compromised Second Molar After Third Molar RemovalBone Defects; Dentin Graft; Impacted Mandibular Third Molar Extraction; XenograftNot yet recruitingNot applicable2026-01-23NCT07362394